DGAP-News: Corporate Update
(firmenpresse) - DGAP-News: Evotec AG / Key word(s): Miscellaneous
Corporate Update
18.03.2013 / 07:29
---------------------------------------------------------------------
Hamburg, Germany - 18 March 2013: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX) today announced that Dr Werner Lanthaler, Chief Executive Officer
of Evotec, will resume his role as Chief Executive Officer of the Company
with immediate effect after a period of leave due to health reasons.
Dr FlemmingØrnskov, Chairman of the Supervisory Board of Evotec AG,
commented: 'The board is delighted to welcome back Dr Lanthaler to resume
his leadership of Evotec and to continue to drive the growth of the Company
through Action Plan 2016. The board would also like to thank the Management
Team of Colin Bond, Dr Cord Dohrmann and Dr Mario Polywka for managing the
company in Dr Lanthaler's absence.'
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca
and Ono Pharmaceutical. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim,
MedImmune and Andromeda (Teva) in the field of diabetes, and with Roche in
the field of Alzheimer's disease. For additional information please go to
www.evotec.com.
Contact Evotec AG:
Gabriele Hansen, Head of Corporate Communications, Phone:
+49.(0)40.56081-255, gabriele.hansen(at)evotec.com
End of Corporate News
---------------------------------------------------------------------
18.03.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info(at)evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAXListed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
204181 18.03.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 18.03.2013 - 07:29 Uhr
Sprache: Deutsch
News-ID 240060
Anzahl Zeichen: 4782
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 196 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Corporate Update"
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
